Allergan, Inc. (AGN): A New Migraine Therapy That Can Address a Major Demand

In addition to upcoming non-triptan drugs, a product from Arteaus Therapeutics is a novel therapy for migraine headaches. Arteaus is developing a monoclonal antibody (LY2951742) in collaboration with Eli Lilly & Co. (NYSE:LLY) for the prevention of migraine attacks.  Y2951742 can be administered subcutaneously once every other week. It can block the Calcitonin Gene Related Peptide or CGRP from binding to its receptor. CGRP has been identified as the principal reason migraine occurs. Unlike other drugs for migraine, this candidate has the potential to attack migraine to its root cause and eradicate it.

The product is in Phase II trial and may be a potential therapy on successful completion of development stages. However, it needs to be noted that CGRP is a useful element of the body physiology and a lot of research still needs to be done to make sure that its blockage does not cause harm to the body.

Conclusion

Currently, Allergan, Inc. (NYSE:AGN)’s Levadex controls about a fifth of the total market share for non-triptan drugs. Its main problem has been its delivery mode. Now, with the inhaler, that problem is about to be resolved. This will give the drug a fighting chance to gain market share in the non-triptan market.

The article A New Migraine Therapy That Can Address a Major Demand originally appeared on Fool.com and is written by Kanak Kanti.

Dr Kanak Kanti De has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Kanak is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.